{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Squamous+Cell+Carcinoma", "query": { "condition": "Rectal Squamous Cell Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 217, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rectal+Squamous+Cell+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T19:10:08.365Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Endometrial Cancer", "Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Bladder Cancer", "Metastatic Castration Resistant Prostate Cancer", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CPI-006", "type": "DRUG" }, { "name": "CPI-006 + ciforadenant", "type": "DRUG" }, { "name": "CPI-006 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-04-25", "completion_date": "2023-02-19", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454451" }, { "nct_id": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Uveal Melanoma", "Cutaneous Melanoma", "Non-Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Turnstone Biologics, Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2023-01-17", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 11, "location_summary": "Irvine, California • Hollywood, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05576077" }, { "nct_id": "NCT05277051", "title": "First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Remzistotug", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Belrestotug", "type": "DRUG" }, { "name": "Nelistotug", "type": "DRUG" }, { "name": "GSK5764227", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 152, "start_date": "2022-03-22", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 7, "location_summary": "San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05277051" }, { "nct_id": "NCT04981119", "title": "Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "CRC", "NSCLC", "Pancreas Cancer", "Mesothelioma", "Ovarian Cancer", "Ovarian Neoplasms", "Ovarian Carcinoma", "Mesothelioma, Malignant", "Mesothelioma; Lung", "Cancer", "Triple Negative Breast Cancer (TNBC)", "Renal Cell Carcinoma (Kidney Cancer)", "Head and Neck Squamous Cell Carcinoma HNSCC" ], "interventions": [ { "name": "Apheresis", "type": "OTHER" }, { "name": "Next Generation Sequencing (NGS)", "type": "DIAGNOSTIC_TEST" }, { "name": "Long Range NGS HLA typing", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2021-10-29", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04981119" }, { "nct_id": "NCT05736731", "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Solid Tumor", "Pancreatic Cancer", "Pancreatic Neoplasms", "Pancreas Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Recurrent", "Non-Small Cell Squamous Lung Cancer", "NSCLC", "NSCLC, Recurrent", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Adenocarcinoma", "CRC", "Colorectal Cancer Metastatic", "Cancer" ], "interventions": [ { "name": "A2B530", "type": "BIOLOGICAL" }, { "name": "xT-Onco with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-04-28", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 8, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05736731" }, { "nct_id": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Non-small-cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Ovarian Carcinoma" ], "interventions": [ { "name": "PF-07826390", "type": "DRUG" }, { "name": "sasanlimab", "type": "BIOLOGICAL" }, { "name": "SOC (anti-PD-1 + platinum -based chemo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2024-09-06", "completion_date": "2025-10-03", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 8, "location_summary": "Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546553" }, { "nct_id": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Colorectal Carcinoma", "Glioblastoma Multiforme" ], "interventions": [ { "name": "ABBV-221", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 46, "start_date": "2015-01-09", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-03-30", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 3, "location_summary": "Boston, Massachusetts • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365662" }, { "nct_id": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Other Tumors With EGFR Dependence" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451632" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT02335918", "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Ovarian Carcinoma-Enrollment Completed", "Colorectal Cancer (CRC)-Enrollment Completed", "Renal Cell Carcinoma (RCC) (Phase ll Only)", "Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed" ], "interventions": [ { "name": "Combination of varlilumab and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-01", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-06-25T19:10:08.365Z", "location_count": 19, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335918" } ] }